These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9807971)

  • 21. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
    Zambón D; Ros E; Rodriguez-Villar C; Laguna JC; Vázquez M; Sanllehy C; Casals E; Sol JM; Hernández G
    Metabolism; 1999 Jan; 48(1):47-54. PubMed ID: 9920144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.
    Knopp RH; Frohlich J; Jokubaitis LA; Dawson K; Broyles FE; Gomez-Coronado D
    Am J Med; 1994 Jun; 96(6A):69S-78S. PubMed ID: 8017470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
    Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
    Kerzner B; Corbelli J; Sharp S; Lipka LJ; Melani L; LeBeaut A; Suresh R; Mukhopadhyay P; Veltri EP;
    Am J Cardiol; 2003 Feb; 91(4):418-24. PubMed ID: 12586255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
    Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
    Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.
    Otto C; Parhofer KG; Ritter MM; Richter WO; Schwandt P
    Br J Clin Pharmacol; 1998 Nov; 46(5):473-8. PubMed ID: 9833601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
    Koev D; Zlateva S; Susic M; Babic D; Profozic V; Skrabalo Z; Langrová H; Cvrkalová AL; Rajecová E; Klimes I
    Diabetes Care; 1993 Sep; 16(9):1285-90. PubMed ID: 8404433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus.
    Solfrizzi V; Capurso C; Colacicco AM; D'Introno A; Fontana C; Capurso SA; Torres F; Gadaleta AM; Koverech A; Capurso A; Panza F
    Atherosclerosis; 2006 Oct; 188(2):455-61. PubMed ID: 16384561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lovastatin lowers serum cholesterol levels in non-insulin-dependent diabetes mellitus patients without altering their insulin sensitivity.
    Hwu CM; Shih KC; Kwok CF; Chang CL; Ho LT
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Mar; 57(3):169-76. PubMed ID: 8935222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome.
    Kasiske BL; Velosa JA; Halstenson CE; La Belle P; Langendörfer A; Keane WF
    Am J Kidney Dis; 1990 Jan; 15(1):8-15. PubMed ID: 2294737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia.
    Barlow CW; Soicher ER; Jankelow D; Myburgh DP
    S Afr Med J; 1990 May; 77(10):504-5. PubMed ID: 2343347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.
    Korhonen T; Hannuksela ML; Seppänen S; Kervinen K; Kesäniemi YA; Savolainen MJ
    Eur J Clin Pharmacol; 1999 Feb; 54(12):903-10. PubMed ID: 10192749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acipimox in the treatment of patients with hyperlipidaemia: a double blind trial.
    Ball MJ; Vella M; Rechlass JP; Jones DB; Stirling C; Mann JI; Galton D
    Eur J Clin Pharmacol; 1986; 31(2):201-4. PubMed ID: 3803417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Influence of lovastatin on serum lipids in patients with primary hyperlipidemia phenotype IIa and IIb. I. Efficacy of lovastatin in the treatment of hyperlipoproteinemia].
    Idzior-Waluś B
    Przegl Lek; 1992; 49(9):287-91. PubMed ID: 1302351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term Acipimox decreases the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport.
    Dullaart RP; van Tol A
    Diabet Med; 2001 Jun; 18(6):509-13. PubMed ID: 11472472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial.
    Lal SM; Hewett JE; Petroski GF; Van Stone JC; Ross G
    Am J Kidney Dis; 1995 Apr; 25(4):616-22. PubMed ID: 7702060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.